Four first or second neighbors of the CAD candidate genes in this module are targets of current cardiometabolic drugs: TFPI (dalteparin), ITGB3 (abciximab and eptifibatide), MMP2 (captopril) and VEGFA (dalteparin) (Table 1, Supplementary Tables 5 and 8), and for these gene-drug pairs CAD relevant physiological effects have been reported (for more details and references see https://www.drugbank.ca)57–63. Here, VEGFA is linked to coronary artery disorder.